La vendita allo scoperto per Monopar Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Monopar Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Monopar Therapeutics (NASDAQ:MNPR) Azioni, Report sulle vendite allo scoperto

MONOPAR THERAPEUTICS INC

Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists ofValidivefor the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Monopar Therapeutics Inc

Baird analyst David Tarantino maintains Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Neutral and lowers the price target from $98 to $85.

News

Price Target

Analyst Ratings

SHAK

Baird Maintains Neutral on Shake Shack, Lowers Price Target to $85

China's&nbsp;DeepSeek, in collaboration with researchers from Tsinghua University, developed a technique to improve the reasoning capabilities of <a target="_blank" href="https://www.benzinga.com/topic/deepseek" rel="noreferrer noopener">large language models (LLMs)</a> that combines generative reward modeling (GRM) and self-principled critique tuning, SCMP <a target="_blank" href="https://www.scmp.com/tech/tech-trends/article/3305259/deepseek-unveils-new-ai-reasoning-method-anticipation-its-next-gen-model-rises" rel="noreferrer noopener">reported</a>, citing a paper published on Friday.
The dual approach aims to enable LLMs to deliver better and faster results to general queries.
Reportedly, the DeepSeek-GRM models outperformed existing methods, according to SCMP, who cited the researchers.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44653936/broadcom-and-marvell-poised-for-growth-as-nvidias-cpo-push-faces-delays-analyst-reveals" rel="noreferrer noopener">Rising Tide Of AI Is So Strong That Semiconductor Optical Industry Projects $30 Billion Total Addressable Market By 2029</a>
DeepSeek aimed to make the GRM models open source. The emergence of&nbsp;DeepSeek&nbsp;and claims of <a target="_blank" href="https://www.benzinga.com/25/03/44511372/alibaba-strikes-back-new-ai-model-takes-on-deepseek-amid-1-trillion-tech-shakeup" rel="noreferrer noopener">affordable AI models</a> fueled a $1 trillion market wipeout in the U.S. and a domestic price war, prompting Chinese Big Tech companies to roll out affordable AI models.
In March, DeepSeek said its upgraded V3 model offered&nbsp;enhanced reasoning capabilities, optimized front-end web development, and upgraded Chinese writing proficiency.
In February, it also&nbsp;open-sourced five of its code repositories. In late February, DeepSeek founder Liang Wenfeng participated in a&nbsp;symposium with tech entrepreneurs&nbsp;hosted by Chinese President Xi Jinping in Beijing.
Chinese e-commerce juggernaut Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44625580/alibaba-steps-up-ai-game-with-qwen-3-challenging-deepseeks-low-cost-ai-success" rel="noreferrer noopener">plans to release</a> an upgraded version of its flagship&nbsp;AI model by April.
DeepSeek's claims prompted China's tech leaders to flood the market with affordable AI services.
OpenAI,&nbsp;Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)&nbsp;Google&nbsp;and&nbsp;Anthropic&nbsp;have similarly released new models.
Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) announced the release of its new Llama 4 artificial intelligence models, built on one of the world's most advanced large language models as <a target="_blank" href="https://ai.meta.com/blog/llama-4-multimodal-intelligence/" rel="noreferrer noopener">per the company</a>.
It is noteworthy that iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>) has gained 10% year-to-date, while iShares China Large-Cap ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) lost over 17%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44652222/trumps-tariffs-may-shift-us-spending-from-goods-to-services-creating-uncertainty-for-ecommerce-and-advertising-industries-analyst-warns" target="_blank" rel="noreferrer noopener">Tariffs To Impact End Demand: Goldman Sachs Analyst Expects Drag On Corporate Spending, Hiring</a></li>
</ul>
Image via Shutterstock

Asia

Tech

Media

BABA

GOOG

GOOGL

NVDA

China's DeepSeek Teams Up With Tsinghua University To Raise AI Bar, Boost Reasoning Capabilities

Baird analyst David Tarantino maintains Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) with a Neutral and lowers the price target from $72 to $65.

Baird Maintains Neutral on Restaurant Brands Intl, Lowers Price Target to $65

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) with a Buy and maintains $81 price target.

Reiteration

ARVN

HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $81 Price Target

Baird analyst David Tarantino maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Neutral and lowers the price target from $310 to $300.

Baird Maintains Neutral on McDonald's, Lowers Price Target to $300

Shares of Mesa Air Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESA#NASDAQ">MESA</a>) are <a href="https://www.benzinga.com/premarket">skyrocketing in premarket </a>on Monday after the merger agreement with Republic Airways Holdings Inc in an all-stock deal to create a major player in the regional airline market.
The combined company will be named Republic Airways Holdings Inc. The transaction is expected to close later in 2025.
The company will remain listed on the NASDAQ under the new RJET ticker.
Once finalized, Republic shareholders will hold 88% of the new company. Mesa shareholders will own between 6% and 12%, depending on certain pre-closing benchmarks.
The agreement includes conditions requiring Mesa to offload specific assets and liabilities, supported by United Airlines. As of June 30, 2024, Mesa held $16.3 milli<a href="https://www.benzinga.com/pressreleases/24/10/g41353277/mesa-air-group-reports-third-quarter-fiscal-2024-results">on in cash and equivalents</a>.
The dealmakers forecast pro forma cash and debt balances post-merger to be $285 million and $1.1 billion, respectively. Mesa will not transfer any outstanding debt.
The combined firm projects an annual revenue of approximately $1.9 billion and an adjusted EBITDA exceeding $320 million.
Also Read: <a href="https://www.benzinga.com/news/asset-sales/25/04/44646240/rogers-scores-5-billion-blackstone-deal-to-cut-debt-unlock-wireless-infrastructure-value">Rogers Scores $5 Billion Blackstone Deal To Cut Debt, Unlock Wireless Infrastructure Value</a>
&#8220;Today&#8217;s announcement is an exciting next step in Mesa&#8217;s more than 40-year history, one that represents the best outcome for our shareholders, employees, and all of our stakeholders,&#8221; said&nbsp;Mesa&#8217;s Chairman and CEO, Jonathan Ornstein.
The current Republic leadership team will guide the merged airline. The new Board will include six Republic directors and one independent Mesa appointee. 
The merger will retain all flight and operations personnel, with continued service to American, Delta, and United. Mesa will support United under a renewed 10-year contract.
Republic Airways, which began operations in 1974, has built itself into one of the largest regional airlines in the U.S., flying more than 17 million passengers annually and operating over 240 Embraer 170/175 aircraft. 
The carrier maintains long-term agreements with American Airlines, Delta Air Lines, and United Airlines, providing consistent revenue streams. In 2024, Republic reported approximately $1.5 billion in revenue and $65 million in net income.
The merger aims to improve operational efficiency, expand route offerings, and increase the financial strength of the newly formed entity.
&#8220;We&#8217;re thrilled to combine the Republic and Mesa teams to create one of the world&#8217;s leading Embraer Jet operators,&#8221; said&nbsp;Republic&#8217;s President and CEO, Bryan Bedford.
The unified airline will operate roughly 310 E-Jet aircraft, performing over 1,250 daily departures, and maintain both companies&#8217; current route networks and FAA certifications until a single operating certificate is secured.
Price Action: MESA shares traded higher by 26.43% at 90 cents in premarket at last check Monday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44651574/fintech-company-klarna-delays-us-ipo-amid-tariff-turmoil-report">Once A $15 Billion IPO Hope, Swedish Fintech Klarna Plans Daunted By Tariffs</a></li>
</ul>
Image: Shutterstock

General

MESA

Regional Airline Shakeup: Republic, Mesa To Merge In All-Stock Deal; Stock Soars

Historian and philosopher Yuval Noah Harari has a message for anyone sleepwalking through the AI revolution: wake up—before the algorithms finish rewriting our reality. 
What Happened: During his recent trip to Japan to promote his book Nexus, Harari warned that artificial intelligence is not just a technological shift — it's an existential one. 
"Now we have created something which is not human — AI — that has mastered language and mathematics better than us," he said in an <a href="https://asia.nikkei.com/Editor-s-Picks/Interview/People-need-to-know-when-they-are-chatting-with-AI-Yuval-Noah-Harari">interview</a> with Nikkei.
<h3 class="wp-block-heading">&#8216;Breeding Ground&#8217;</h3>
Harari pointed to social media as a breeding ground for chaos, fueled by bots that impersonate people and flood platforms with fake news, conspiracy theories, and rage — all to drive engagement. 
"The two most obvious countermeasures are, first of all, to ban fake humans," he said. "They are welcome to talk with human beings only if they clearly identify themselves as AIs." He stressed the psychological manipulation that occurs when people believe a trending story is organically popular, not realizing it's being pushed by a swarm of bots.
See also: <a href="https://www.benzinga.com/tech/25/04/44656079/bill-gates-satya-nadella-and-steve-ballmer-get-roasted-by-microsofts-ai-copilot-lets-spice-it-up">Bill Gates, Satya Nadella, And Steve Ballmer Get Roasted By Microsoft&#8217;s AI Copilot: &#8216;Let&#8217;s Spice It Up&#8217;</a>
The second safeguard, he said, involves accountability: "Companies should be liable for the actions of their algorithms." He dismissed the common defense of free speech, saying, "The problem is not what human beings are saying. The problem is the decisions of algorithms."
<h3 class="wp-block-heading">Harari&#8217;s Views On Politics</h3>
On politics, Harari didn't hold back. He said, "Democracy is all about self-correcting mechanisms. The danger is: What if you give power to somebody that doesn't want to give it back?" He described Trump's worldview as one where "the strong rule and the weak must obey the strong," warning that such thinking could escalate global militarization and undermine cooperation.
Harari also sounded the alarm over AI monopolies: "It would be very dangerous if only two countries or a few countries monopolize AI technology." He urged global cooperation, especially among nations like Japan, India, Brazil, and the EU, to prevent domination by the U.S. and China.
Despite the warnings, Harari sees hope. "AI can invent new medicines, can help us deal with climate change," he said. But he cautioned that its unpredictability makes it "an alien intelligence." The challenge now? "You cannot predict what kind of ideas AI will invent or what kind of decision it will make."
<h3 class="wp-block-heading">Criticism From The Scientific Community, Academics</h3>
Yuval Noah Harari&#8217;s Sapiens has faced criticism from scientists and academicians for its speculative approach and lack of rigorous evidence. Anthropologist Christopher Robert Hallpike <a href="https://www.newenglishreview.org/articles/a-response-to-yuval-hararis-sapiens-a-brief-history-of-humankind/">dismissed</a> the book as making no &#8220;serious contribution to knowledge,&#8221; describing it as infotainment filled with sensational speculation rather than substantive analysis. Similarly, Charles C. Mann critiqued Harari&#8217;s assertions as unsourced and <a href="https://www.wsj.com/articles/book-review-sapiens-a-brief-history-of-humankind-by-yuval-noah-harari-1423261230">overly simplistic</a>, likening them to &#8220;dorm-room bull sessions&#8221;.
Moreover, Harari&#8217;s evolutionary explanations for religion and human cognition have been called <a href="https://www.discovery.org/a/review-of-yuval-noah-hararis-sapiens/">reductive</a>; his reliance on &#8220;accidental genetic mutations&#8221; and naturalistic assumptions oversimplifies complex phenomena, failing to account for deeper religious and societal intricacies. Such critiques highlight the book&#8217;s tendency toward engaging narrative over scientific rigor.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/25/04/44663080/apple-facebook-and-google-become-bargaining-chips-in-us-trade-war-eu-threatens-retaliation-uk-offers-tax-relief-for-lower-tariffs">Apple, Facebook, And Google Become Bargaining Chips In US Trade War: EU Threatens Retaliation, UK Offers Tax Relief For Lower Tariffs</a>

Entertainment

Education

Politics

Yuval Harari Says AI Bots Should Identify Themselves Or Stay Silent, 'You Cannot Predict What Kind Of Ideas AI Will Invent'

Baird analyst David Tarantino maintains Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Neutral and lowers the price target from $34 to $25.

JACK

Baird Maintains Neutral on Jack In The Box, Lowers Price Target to $25

Better Choice Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#NYSE">BTTR</a>) ("Better Choice" or the "Company"), a pet health and wellness company, today announced that its Board of Directors have approved a stock dividend of 0.35 per share for every 1 share held of common stock, which will be payable to stockholders of record as of Thursday, April 17, 2025.
The stock dividend will be distributed to all registered shareholders who are on record as of 5:00 p.m. ET on April 17, 2025 and shares will then be issued at 7:59 p.m. ET on the same day.

Dividends

BTTR

Better Choice Company Board Of Directors Have Approved A Stock Dividend Of 0.35 Per Share For Every 1 Share Held Of Common Stock

UBS analyst Steven Fisher downgrades PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) from Neutral to Sell and lowers the price target from $108 to $78.

Downgrades

PCAR

UBS Downgrades PACCAR to Sell, Lowers Price Target to $78

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Buy and maintains $10 price target.

SGMO

HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

Baird analyst David Tarantino maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Neutral and lowers the price target from $210 to $192.

Baird Maintains Neutral on Darden Restaurants, Lowers Price Target to $192

Management

JNVR

Former Kraken Team Acquires Majority Stake In Janover, Appoints New Leadership Including Joseph Onorati As CEO, Adopts Treasury Policy To Focus On Digital Assets With Solana Staking And Validator Business, While Continuing SaaS Transition And Retaining Key Executives

Janover, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JNVR#NASDAQ">JNVR</a>) (the "Company") announced today that it had raised approximately $42 million in an offering of convertible notes and warrants from Pantera Capital, Kraken, Arrington Capital, Protagonist, The Norstar Group, Third Party Ventures, Trammell Venture Partners, and 11 angel investors. The notes were sold in a private offering under Section 4(a)(2) under the Securities Act of 1933, as amended (the "Securities Act") and Regulation D promulgated thereunder.
The aggregate principal amount of the convertible notes sold in the offering was approximately $42 million, which are convertible into the Company's common stock, par value $0.00001 per share ("Common Stock"). The convertible notes accrue interest at a rate of 2.5% per year, paid in cash quarterly in arrears, and mature on April 6, 2030. The convertible notes are convertible at any time prior to the maturity date, conditioned on the requirement that the Company's market capitalization equaled or exceeded $100 million on the day prior to the conversion date. The conversion price will be set on the date that the Company's market capitalization first equals or exceeds $100 million to equal the last reported sale price of the Common Stock on The Nasdaq Stock Market, subject to a minimum conversion price of $4.81. For each $1,000 in principal amount of convertible notes purchased, warrants were issued to purchase (1) approximately 8.333 shares of Common Stock at an exercise price of $120 per share and (2) approximately 6.666 shares of Common Stock at an exercise price of $150 per share. The conversion price and exercise price, respectively, are subject to customary anti-dilution and dividend protections.

Offerings

Janover Raises $42M In Convertible Notes And Warrants From Pantera Capital, Kraken, Arrington Capital, And Others, With Proceeds Aimed At Acquiring Digital Assets, Starting With The Solana Ecosystem, And Enhancing Efforts In The U.S. Public Markets

Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) shares were trading lower in premarket on Monday after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44660686/shell-first-quarter-2025-update-note" rel="noreferrer noopener">revised&nbsp;its first-quarter&nbsp;outlook</a>.
For the&nbsp;first quarter, it cut the guidance for production at Integrated Gas to around 910 &#8211; 950 thousand boe/d (vs. the prior outlook of 930 – 990&nbsp;thousand boe/d) due to unplanned maintenance, mainly in Australia.
Also, Shell revised the outlook for Upstream to about 1,790 &#8211; 1,890 thousand boe/d <a target="_blank" href="https://www.benzinga.com/news/buybacks/25/01/43332871/shell-q4-lower-earnings-cost-reductions-dividend-boost-and-more" rel="noreferrer noopener">(vs. earlier outlook of 1,750 – 1,950 thousand boe/d)</a>, reflecting the completion of the SPDC divestment in March 2025.
In the Upstream segment, the company projects a share of profit / (loss) of joint ventures and associates of ~$200 million and exploration well write-offs of ~$0.1 billion in the quarter.
The company now projects Marketing sales volumes of&nbsp;around 2,500 &#8211; 2,900 thousand b/d (vs. earlier guidance of 2,500 – 3,000 thousand b/d), reflecting a lower contribution from Sectors &amp; Decarbonisation.
Shell anticipates refinery utilization of around&nbsp;83% – 87% (vs. prior outlook of 80% – 88%) and chemical manufacturing plant utilization of between&nbsp;79% – 83% <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">(vs. earlier guidance of 78% – 86%)</a>.
The company expects Trading &amp; Optimisation to be significantly higher than the fourth quarter of FY24 in Chemicals and Products segment.
The company also adjusted its LNG production forecast, now predicting between 6.4 million and 6.8 million metric tons from a previous&nbsp;guidance&nbsp;of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g43327844/shell-plc-publishes-fourth-quarter-2024-press-release" rel="noreferrer noopener">6.6 million – 7.2 million metric tons</a>.
Last month, at Capital Markets Day 2025,&nbsp;Shell&nbsp;disclosed plans to increase shareholder distributions from&nbsp;30%-40%&nbsp;to&nbsp;40%-50%&nbsp;of cash flow from operations&nbsp;<a target="_blank" href="https://www.benzinga.com/news/guidance/25/03/44470278/shell-unveils-new-strategy-higher-buybacks-cost-cuts-and-10-annual-free-cash-flow-growth" rel="noreferrer noopener">(CFFO) throughout economic cycles</a>.
Shell has raised its structural cost reduction target from&nbsp;$2-3 billion by the end of 2025 to a cumulative&nbsp;$5-7 billion by 2028,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">based on 2022 levels</a>.
Investors can gain exposure to the stock via&nbsp;Precidian ETFs Trust Shell plc ADRhedged&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/SHEH#BATS">SHEH</a>) and&nbsp;Abacus FCF Real Assets Leaders ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ABLD#BATS">ABLD</a>).
Price Action: SHEL shares are trading lower by&nbsp;4.80%&nbsp;at&nbsp;$61.05 premarket at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/guidance/25/04/44644795/brookfield-strikes-9-billion-deal-for-colonial-pipeline-shell-offloads-minority-stake" target="_blank" rel="noreferrer noopener">Brookfield Strikes $9 Billion Deal For Colonial Pipeline—Shell Offloads Minority Stake</a></li>
</ul>
Photo via Shutterstock

Equities

Large Cap

Movers

ABLD

AstraZeneca PLC ADRhedged Shell plc ADRhedged

SHEH

SHEL

Shell Lowers Q1 Production Outlook, Flags Write-Offs And Maintenance

Baird analyst David Tarantino maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Outperform and lowers the price target from $510 to $500.

Baird Maintains Outperform on Domino's Pizza, Lowers Price Target to $500

UBS analyst Thomas Wadewitz downgrades United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) from Buy to Neutral and lowers the price target from $107 to $59.

UBS Downgrades United Airlines Holdings to Neutral, Lowers Price Target to $59

Baird analyst David Tarantino maintains Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Outperform and lowers the price target from $68 to $62.

Baird Maintains Outperform on Chipotle Mexican Grill, Lowers Price Target to $62

<a href="https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility" title="https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility">https://www.jnj.com/media-center/press-releases/european-commission-approves-johnson-johnsons-subcutaneous-darzalex-daratumumab-based-quadruplet-regimen-for-the-treatment-of-patients-with-newly-diagnosed-multiple-myeloma-regardless-of-transplant-eligibility</a>

Biotech

Johnson & Johnson Announces The European Commission Has Approved Its Subcutaneous Darzalex-Based Quadruplet Regimen For The Treatment Of Patients With Newly Diagnosed Multiple Myeloma, Regardless Of Transplant Eligibility

Baird analyst David Tarantino maintains Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Outperform and lowers the price target from $125 to $105.

CAVA

Baird Maintains Outperform on Cava Group, Lowers Price Target to $105

Health Care

Press Releases

Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

IPOs

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

Financing

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

Earnings

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics

Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments

MNPR

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Monopar Therapeutics

Vendite allo scoperto

Monopar Therapeutics (NASDAQ:MNPR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO